We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
NC6OB | Nanollose Limited | 0.008 | 0.004 | 100.00% | 200,000 | 2 |
LPDOE | Lepidico Ltd | 0.002 | 0.001 | 100.00% | 1,583,642 | 4 |
RC1O | Redcastle Resources Ltd | 0.005 | 0.002 | 66.67% | 1,120,998 | 4 |
AHN | Athena Resources Limited | 0.003 | 0.001 | 50.00% | 350,000 | 2 |
YPB | YPB Group Ltd | 0.003 | 0.001 | 50.00% | 5,258,747 | 17 |
APC | Australian Potash Limited | 0.0015 | 0.0005 | 50.00% | 2,375,610 | 18 |
NC6 | Nanollose Limited | 0.032 | 0.009 | 39.13% | 225,424 | 6 |
LGMO | Legacy Minerals Holdings Ltd | 0.065 | 0.018 | 38.30% | 297,056 | 7 |
WNX | Wellnex Life Ltd | 0.029 | 0.008 | 38.10% | 3,119,671 | 36 |
POS | Poseidon Nickel Limited | 0.006 | 0.0015 | 33.33% | 23,371,388 | 192 |
OSXO | Osteopore Limited | 0.012 | 0.003 | 33.33% | 225,000 | 1 |
VICTORIA, BC, May 14, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that initial results from the ongoing Phase 1b study of EP-104GI for the treatment of eosinophilic esophagitis will be presented at the upcoming Digestive Disease Week ("DDW") Annual Meeting 2024.
Organic growth investments expected to accelerate financial performance in late fiscal 2026 and into fiscal 2027 Company provides update on third and fourth quarter fiscal 2024 LEBANON, Tenn., May 16, 2024 /PRNewswire/ -- Cracker Barrel Old Country Store, Inc. ("Cracker Barrel" or the "Company") (Nasdaq: CBRL) today provided an update on its strategic transformation plan and announced changes to its capital allocation.
SAN DIEGO, May 14, 2024 /PRNewswire/ -- Kintara Therapeutics, Inc. (Nasdaq: KTRA) ("Kintara" or the "Company"), a biopharmaceutical company focused on the development of new solid tumor cancer therapies, today announced financial results for its fiscal third quarter ended March 31, 2024, and recent corporate developments.
GARDENA, CA, May 15, 2024 (GLOBE NEWSWIRE) -- Polar Power, Inc. (“Polar Power” or the “Company”) (NASDAQ: POLA), a global provider of prime, backup, and solar hybrid DC power solutions, reports its financial results for the first quarter of 2024. Q1 2024 Financial Highlights ●Net sales of $1.8 million compared to $4.2 million in the same period in 2023●Operating expenses of $1.6 million compared to $1.7 million in the same period in 2023●Net loss was $2.1 million, or $(0.12) per basic and diluted share, compared to a net loss of $1.1 million, or $(0.09) ...
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 66,312.58 | 1,073.34 | 1.65% | 1.3T | 4,221,215,673 |
ETH | Ethereum | 3,033.14 | 87.89 | 2.98% | 364.66B | 2,101,367,955 |
USDT | Tether USD | 1.00 | 0.00 | 0.00% | 97.84B | 267,965,443 |
BNB | Binance Coin | 579.14 | 9.80 | 1.72% | 91.44B | 270,963,445 |
SOL | Solana | 167.81 | 8.60 | 5.40% | 74.14B | 1,379,458,939 |
STETH | stETH | 3,032.22 | 101.75 | 3.47% | 29.74B | 4,964,667 |
XRP | Ripple | 0.5214 | 0.0056 | 1.09% | 28.41B | 288,811,877 |
USDC | USD Coin | 0.9999 | -0.0001 | -0.01% | 28.07B | 886,929,822 |
TONCOIN | Wrapped TON Coin | 6.69 | -0.060543 | -0.90% | 23.18B | 384,156,592 |
DOGE | Dogecoin | 0.15224 | 0.00255 | 1.70% | 21.83B | 347,854,831 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions